Clinical Trial Update: SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of SVV-001 with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinoma or we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• OPDIVO (nivolumab)
• SVV-001 (Seneca Valley virus)
• Yervoy (ipilimumab)

Snippet

Sponsor: Peter Hosein, MD | Conditions: Neuroendocrine Carcinoma, Neuroendocrine Tumors | Phase 1 | Status: RECRUITING